• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of June 10


The Center for Biosimilars® recaps the top stories for the week of June 10, 2019.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of June 10.

Number 5: The American Medical Association has issued a call for intensified oversight of the pharmacy benefit manager industry.

Number 4: In 3 late-breaking poster presentations at the American Diabetes Association’s 79th Scientific Sessions, researchers presented data on Sanofi’s proposed insulin aspart biosimilar.

Number 3: During the European League Against Rheumatism Annual European Congress of Rheumatology, multiple research teams shared real-world evidence on biosimilar etanercept, SB4.

Number 2: A research letter in JAMA Internal Medicine raises the question of whether there is room for increased FDA transparency about regulatory filings.

Number 1: Experts weighed in on the Biosimilars Forum’s policy proposals that the group says could save the United States billions.

Finally, last week, our e-newsletter asked whether you think other payers will follow UnitedHealthcare’s lead in preferring reference pegfilgrastim over biosimilar options.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Related Content
© 2024 MJH Life Sciences

All rights reserved.